アンジェス(株)【4563】の掲示板 2017/10/24〜2017/10/26

SAN DIEGO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (VICL) announced today that it is pursuing early stage development of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. This development effort is being conducted in collaboration with Vical’s strategic partner, AnGes, Inc of Osaka, Japan. The initial stage of this program will be to demonstrate preclinical proof of concept for inhibiting HBV infection in a human liver model in the second half of 2018. The ultimate aim of this program would be to demonstrate eradication of persistent HBV infection in CHB patients.